Navigation Links
Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009
Date:10/29/2008

important indicator of the strength and the performance of our business as they provide a link to operating cash flow. We also believe that analysts and investors use such measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating performance improved from a loss of approximately $0.6 million and $1 million, respectively, for the three and six months ended September 30, 2007 to a (loss) gain of approximately ($98,000) and $8,000, respectively, for the three and six months ended September 30, 2008. We attribute this improvement in non-GAAP operating performance to the increase in sales and an improvement in gross margin rate, offset partially by an increase in cash operating expenses.

Three Months Ended Six Months Ended

September 30, September 30,

2008 2007 2008 2007

Gross Profit

GAAP gross profit 3,371,317 $2,370,502 7,188,972 $4,724,964

% of sales 86% 78% 85% 79%

SFAS 123 (R)

share-based

compensation 8,879 9,107 25,253 9,686

Depreciation

expenses 13,057 13,054 25,847 28,604

Non-GAAP gross

profit 3,393,253 2,392,663 7,240,072 4,763,254

Operating Expenses

GAAP operating

expenses 3,962,936 3,755,494 8,238,179 $6,919,303

SFAS 123 (R)

share-based

compensation 198,131 494,449 464,748 660,956

Depreciation

expenses 62,104 46,379 119,161 78,159

Amortization

expenses 210,966
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference
2. Uroplasty to Host First Quarter Conference Call on July 31
3. Uroplasty Joins the Russell Microcap Index
4. Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008
5. Uroplasty to Host Fourth Quarter and Year End Conference Call on June 3
6. Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annual Meeting
7. Uroplasty Plans to Double Sales Force During Fiscal 2009
8. Uroplasty, Inc. Reports Presentations of Urgent(R) PC Studies at the 2008 Society of Urologic Nurses and Associates Annual Symposium
9. Uroplasty to Present at ROTH Capital Partners 20th Annual OC Growth Stock Conference
10. Uroplasty Expands Marketing Program for Urology Practices
11. Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Phoenix Health Systems and SunGard Availability Services Partner to Deliver Data and IT Management Solutions to Community Hospitals 2Health News:Phoenix Health Systems and SunGard Availability Services Partner to Deliver Data and IT Management Solutions to Community Hospitals 3Health News:Plaques, Tangles in Brain Don't Always Lead to Alzheimer's 2Health News:UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 4Health News:Deadline Extended for Nominations for Jay and Rose Phillips Awards and Phillips Caregiver Award 2
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 2AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 3AcceleDent Science is Showcased in New Continuing Education Course Published by PennWell 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3NC State receives NSF grant to discover plant switchboards 9774 1NC State receives NSF grant to discover plant switchboards 9774 2NC State receives NSF grant to discover plant switchboards 9774 3Researchers design new graphene based nano material with magnetic properties 13810 1Researchers design new graphene based nano material with magnetic properties 13810 2Pew poll 3A 9 in 10 Iowa voters support more government oversight of food 56091 1Pew poll 3A 9 in 10 Iowa voters support more government oversight of food 56091 2
Other Medicine Technology:BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6